

Rossella Elisei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4949400/publications.pdf>

Version: 2024-02-01

329
papers

28,092
citations

7551

77
h-index

6113

159
g-index

357
all docs

357
docs citations

357
times ranked

13967
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. <i>Seminars in Cancer Biology</i> , 2022, 79, 197-202.	4.3	18
2	2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	62
3	Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018. <i>Thyroid</i> , 2022, 32, 263-272.	2.4	4
4	Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center. <i>Cancers</i> , 2022, 14, 420.	1.7	5
5	Response to Letter to the Editor From Green and Gosmanov: "Tall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patients' Clinical Management". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	0
6	Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. <i>Oncologist</i> , 2022, 27, 565-572.	1.9	12
7	IMPACT OF ENERGY-BASED DEVICES IN PEDIATRIC THYROID SURGERY. <i>Journal of Pediatric Surgery</i> , 2022, , .	0.8	0
8	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. <i>Frontiers in Endocrinology</i> , 2022, 13, 864253.	1.5	17
9	Nutrition in Advanced Thyroid Cancer Patients. <i>Nutrients</i> , 2022, 14, 1298.	1.7	4
10	Clinical "Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 842424.	1.5	5
11	Bilateral testicular metastases of medullary thyroid carcinoma in an adult male with multiple endocrine neoplasia 2A syndrome: case report and review of literature. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	1
12	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	2.4	9
13	Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3420-e3427.	1.8	8
14	Predictive Biomarkers in Thyroid Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
15	Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2195-2202.	1.8	14
16	Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7470.	1.8	5
17	Proteinuria is a late-onset adverse event in patients treated with cabozantinib. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 95-103.	1.8	16
18	Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al.. <i>Thyroid</i> , 2021, 31, 330-331.	2.4	2

#	ARTICLE	IF	CITATIONS
19	First report of benign track seeding after robot-assisted transaxillary thyroid surgery. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102811.	0.6	4
20	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. Thyroid, 2021, 31, 1050-1055.	2.4	11
21	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. Thyroid, 2021, 31, 1056-1066.	2.4	3
22	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Thyroid, 2021, 31, 224-232.	2.4	30
23	Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma. Endocrine, 2021, 72, 140-146.	1.1	2
24	Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. Minerva Endocrinologica, 2021, 45, 306-317.	1.7	6
25	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. International Journal of Cancer, 2021, 148, 2935-2946.	2.3	11
26	RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells. Endocrine Connections, 2021, 10, 124-130.	0.8	3
27	A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. International Journal of Molecular Sciences, 2021, 22, 1726.	1.8	48
28	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. Endocrine, 2021, 72, 332-339.	1.1	10
29	Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. Journal of Endocrinological Investigation, 2021, 44, 2139-2151.	1.8	17
30	Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. International Journal of Molecular Sciences, 2021, 22, 3117.	1.8	36
31	[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2355-2366.	1.8	10
32	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid, 2021, 31, 1226-1234.	2.4	24
33	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.1	3
34	Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4109-e4117.	1.8	13
35	Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. Cancers, 2021, 13, 3200.	1.7	15
36	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4072-e4083.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. <i>Cancers</i> , 2021, 13, 3123.	1.7	14
38	Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2557-2566.	1.8	9
39	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103366.	2.0	7
40	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	1.8	36
41	MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy. <i>European Journal of Endocrinology</i> , 2021, 185, R23-R34.	1.9	18
42	Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selipratinib: a case report. <i>Annals of Oncology</i> , 2021, 32, 1447-1449.	0.6	13
43	Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2021, 185, 193-200.	1.9	20
44	Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4068.	1.0	7
45	Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2021, 10, 399-407.	1.2	19
46	Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma. <i>Cancers</i> , 2021, 13, 94.	1.7	14
47	Higher RET Gene Expression Levels Do Not Represent an Alternative RET Activation Mechanism in Medullary Thyroid Carcinoma. <i>Biomolecules</i> , 2021, 11, 1542.	1.8	5
48	RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency. <i>Genes</i> , 2021, 12, 35.	1.0	2
49	Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases. , 2021, , 327-335.		0
50	Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia. <i>Cancers</i> , 2021, 13, 5554.	1.7	5
51	Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2020, 26, 58-71.	1.1	14
52	Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 109-116.	1.8	18
53	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e172-e180.	1.8	94
54	<i>BRAF</i> V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020, 124, 161-169.	1.3	41

#	ARTICLE	IF	CITATIONS
55	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1124-e1134.	1.8	21
56	1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). <i>Annals of Oncology</i> , 2020, 31, S1091.	0.6	3
57	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion. <i>Case Reports in Endocrinology</i> , 2020, 2020, 1-7.	0.2	3
58	Response to Letter to the Editor: "Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2690-e2691.	1.8	0
59	Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2845-e2852.	1.8	7
60	Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up. <i>Endocrine</i> , 2020, 68, 607-616.	1.1	11
61	Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. <i>Frontiers in Endocrinology</i> , 2020, 11, 381.	1.5	10
62	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	0.8	33
63	Polymorphisms Within the <i>RET</i> Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 1579-1588.	2.4	4
64	Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?. <i>International Journal of Cancer</i> , 2020, 147, 2838-2846.	2.3	15
65	Firm mass in thyroid of an elderly patient: not always cancer. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	1
66	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020, 27, 97-110.	1.6	28
67	Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. <i>Endocrine Practice</i> , 2020, 26, 807-817.	1.1	15
68	MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
69	MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
70	Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. <i>Endocrine-Related Cancer</i> , 2020, 27, 97-110.	1.6	8
71	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. <i>European Journal of Cancer</i> , 2019, 118, 35-40.	1.3	70
72	Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas. <i>Endocrine</i> , 2019, 65, 623-629.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. <i>Cancers</i> , 2019, 11, 1516.	1.7	21
74	Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. <i>Genes</i> , 2019, 10, 698.	1.0	49
75	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2019, 8, 227-245.	1.2	179
76	Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. <i>IScience</i> , 2019, 20, 324-336.	1.9	122
77	Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-4.	0.2	4
78	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2520-2526.	1.8	15
79	Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. <i>Annales D'Endocrinologie</i> , 2019, 80, 187-190.	0.6	13
80	Medullary Thyroid Cancer. , 2019, , 673-691.		0
81	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. <i>Frontiers in Oncology</i> , 2019, 9, 1390.	1.3	3
82	Management of Medullary Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 285-301.	1.2	68
83	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26.	2.4	122
84	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 213-220.	5.5	86
85	Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. <i>European Thyroid Journal</i> , 2019, 8, 90-95.	1.2	9
86	Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 241-250.	1.6	20
87	<i>DICER1</i> somatic mutations strongly impair miRNA processing even in benign thyroid lesions. <i>Oncotarget</i> , 2019, 10, 1785-1797.	0.8	20
88	A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. <i>Molecular and Clinical Oncology</i> , 2018, 8, 449-452.	0.4	0
89	mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1389-1399.	1.8	16
90	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60

#	ARTICLE	IF	CITATIONS
91	Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. <i>Head and Neck</i> , 2018, 40, 1752-1758.	0.9	30
92	Use of low-dose radioiodine ablation for Graves's™ orbitopathy: results of a pilot, perspective study in a small series of patients. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 357-361.	1.8	5
93	Thyroid Carcinoma. , 2018, , 573-585.		2
94	Patient Age's Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	0.8	102
95	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	0.8	58
96	Medullary Thyroid Cancer: Diagnosis and Non Surgical Management. , 2018, , 223-239.		0
97	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. <i>Frontiers in Endocrinology</i> , 2018, 9, 590.	1.5	5
98	RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. <i>Oncotarget</i> , 2018, 9, 9875-9884.	0.8	33
99	Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. <i>Oncology Letters</i> , 2018, 15, 9174-9182.	0.8	25
100	Medullary Carcinoma. <i>Endocrinology</i> , 2018, , 589-627.	0.1	0
101	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without ¹³¹ I Ablation. <i>Thyroid</i> , 2018, 28, 871-879.	2.4	35
102	SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i388-i389.	0.4	1
103	The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. <i>Archives of Toxicology</i> , 2018, 92, 2137-2140.	1.9	8
104	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 849-876.	1.8	165
105	Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. <i>Thyroid</i> , 2018, 28, 1318-1324.	2.4	6
106	Medullary Carcinoma. <i>Endocrinology</i> , 2018, , 1-39.	0.1	0
107	Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform ¹³¹ I ablation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2860.	1.8	36
108	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	1.3	59

#	ARTICLE	IF	CITATIONS
109	Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 207-214.	1.2	0
110	Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restrification and Decision to Perform 131I Ablation". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1785-1786.	1.8	1
111	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 319-334.	2.2	26
112	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
113	Targeted Therapy in Thyroid Cancer: State of the Art. <i>Clinical Oncology</i> , 2017, 29, 316-324.	0.6	110
114	Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations. <i>Journal of Surgical Oncology</i> , 2017, 116, 1197-1199.	0.8	4
115	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2813-2819.	0.6	166
116	Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 644-660.	4.3	324
117	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3091-3096.	1.8	2
118	Role of YAP-1 in Thyroid Tumor Progression and Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 581-585.	0.6	7
119	Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. <i>Thyroid</i> , 2017, 27, 1267-1276.	2.4	28
120	Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 55-62.	1.8	25
121	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. , 2017, , 545-583.		1
122	Inherited variants in genes somatically mutated in thyroid cancer. <i>PLoS ONE</i> , 2017, 12, e0174995.	1.1	5
123	Calcitonin receptor expression in medullary thyroid carcinoma. <i>PeerJ</i> , 2017, 5, e3778.	0.9	4
124	Radionuclide Therapy of Thyroid Tumors. , 2017, , 1197-1241.		1
125	Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6467-6477.	1.0	36
126	New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. <i>Journal of Medical Genetics</i> , 2016, 53, 729-734.	1.5	61

#	ARTICLE	IF	CITATIONS
127	Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. <i>Endocrine-Related Cancer</i> , 2016, 23, R185-R205.	1.6	154
128	Reply to the Letter to the Editor by Sollini M et al.. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 487-488.	1.8	2
129	Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. <i>DNA Repair</i> , 2016, 41, 27-31.	1.3	5
130	Runs of homozygosity and inbreeding in thyroid cancer. <i>BMC Cancer</i> , 2016, 16, 227.	1.1	17
131	Correlative analyses of <i>RET</i> and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. <i>Cancer</i> , 2016, 122, 3856-3864.	2.0	81
132	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4413-4420.	1.8	45
133	A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer. , 2016, , 899-910.		1
134	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2016, 5, 187-194.	1.2	11
135	Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. <i>Archives of Toxicology</i> , 2016, 90, 3099-3109.	1.9	9
136	A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy. , 2016, , 355-363.		0
137	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 264-274.	1.8	179
138	A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. <i>Nature Reviews Endocrinology</i> , 2016, 12, 192-202.	4.3	265
139	A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 700-713.	1.1	22
140	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 341-347.	1.8	30
141	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 44-53.	3.2	193
142	Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. <i>Current Pediatric Reviews</i> , 2016, 12, 280-285.	0.4	9
143	Radionuclide Therapy of Thyroid Tumors. , 2016, , 1-47.		0
144	Diagnostic Applications of Nuclear Medicine: Thyroid Tumors. , 2016, , 1-40.		1

#	ARTICLE	IF	CITATIONS
145	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015, 121, 2749-2756.	2.0	159
146	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. <i>Scientific Reports</i> , 2015, 5, 8922.	1.6	23
147	Cabozantinib: an orphan drug for thyroid cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1469-1477.	0.5	1
148	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4387-4395.	1.8	12
149	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 621-630.	13.9	1,526
150	Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1316-1324.	1.8	240
151	Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. <i>European Journal of Endocrinology</i> , 2015, 173, 297-304.	1.9	29
152	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	2.4	1,738
153	Effects of radioiodine treatment for differentiated thyroid cancer on testis function. <i>Clinical Endocrinology</i> , 2015, 82, 295-299.	1.2	13
154	Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?. <i>Clinical Endocrinology</i> , 2015, 82, 892-899.	1.2	46
155	Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 42-50.	0.8	448
156	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11
157	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6012-6012.	0.8	25
158	Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6013-6013.	0.8	4
159	Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6014-6014.	0.8	2
160	Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6015-6015.	0.8	2
161	Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹ I-refractory differentiated thyroid cancer in SELECT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6048-6048.	0.8	8
162	Clinical Case Seminar in Pediatric Thyroid Disease. <i>Endocrine Development</i> , 2014, 26, 214-244.	1.3	2

#	ARTICLE	IF	CITATIONS
163	Novel Genome-Wide Association Study-Based Candidate Loci for Differentiated Thyroid Cancer Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2084-E2092.	1.8	41
164	Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. <i>Thyroid</i> , 2014, 24, 966-974.	2.4	92
165	Medullary Thyroid Carcinoma in Children. <i>Endocrine Development</i> , 2014, 26, 202-213.	1.3	13
166	FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. <i>Thyroid</i> , 2014, 24, 339-346.	2.4	23
167	Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck) Tj ETQq1 1 0.784314 rgBT /Overlook negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 967-972.	1.8	7
168	Randomized Safety and Efficacy Study of Foscarnet with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2014, 24, 232-240.	2.4	130
169	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet</i> , 2014, 384, 319-328.	6.3	1,295
170	Molecular Profiles of Papillary Thyroid Tumors Have Been Changing in the Last Decades: How Could We Explain It?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 412-414.	1.8	10
171	DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. <i>European Journal of Endocrinology</i> , 2014, 171, R33-R46.	1.9	94
172	How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 331-344.	1.2	16
173	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6060-6060.	0.8	14
174	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6061-6061.	0.8	6
175	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6008-LBA6008.	0.8	7
176	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ¹³¹ I-refractory differentiated thyroid cancer (SELECT). <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6008-LBA6008.	0.8	23
177	Incidental versus clinically evident thyroid cancer: A 5-year follow-up study. <i>Head and Neck</i> , 2013, 35, 408-412.	0.9	7
178	Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. <i>Thyroid Research</i> , 2013, 6, S2.	0.7	30
179	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
180	Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. <i>Mutation Research - Reviews in Mutation Research</i> , 2013, 752, 36-44.	2.4	72

#	ARTICLE	IF	CITATIONS
181	Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2121-2125.	1.1	7
182	Genome-Wide Association Study on Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1674-E1681.	1.8	101
183	Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. <i>Thyroid</i> , 2013, 23, 1211-1225.	2.4	152
184	Thyroid and Parathyroid Tumors. , 2013, , 297-361.		0
185	Evidence of a Low Prevalence of <i>RAS</i> Mutations in a Large Medullary Thyroid Cancer Series. <i>Thyroid</i> , 2013, 23, 50-57.	2.4	151
186	Cabozantinib in Progressive Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3639-3646.	0.8	989
187	Nuove indicazioni all'impiego del TSH umano ricombinante (rhTSH) e basse attività di ¹³¹ I nella radioablazione del residuo tiroideo post-chirurgico. <i>L Endocrinologo</i> , 2013, 14, 255-260.	0.0	0
188	Medullary Thyroid Cancer Secreting Carbohydrate Antigen 19-9 (Ca 19-9): A Fatal Case Report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3550-3554.	1.8	23
189	<i>TPO</i> genetic variants and risk of differentiated thyroid carcinoma in two European populations. <i>International Journal of Cancer</i> , 2013, 133, 2843-2851.	2.3	23
190	Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity ¹³¹ I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2693-2700.	1.8	61
191	Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. <i>Future Oncology</i> , 2013, 9, 1083-1092.	1.1	76
192	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	23
193	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	48
194	Follicular-derived neoplasms: morphometric and genetic differences. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 1055-61.	1.8	7
195	Reply to J.-F. Chatal et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2166-2167.	0.8	0
196	The <i>BRAF</i> V600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4390-4398.	1.8	213
197	Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1758-E1765.	1.8	83
198	Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 134-141.	0.8	1,295

#	ARTICLE	IF	CITATIONS
199	The Timing of Total Thyroidectomy in <i>RET</i> Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 426-435.	1.8	119
200	Advances in the follow-up of differentiated or medullary thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2012, 8, 466-475.	4.3	77
201	Chromosome 10 and <i>RET</i> gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2012, 348, 176-182.	1.6	19
202	Low Prevalence of the Somatic M918T <i>RET</i> Mutation in Micro-Medullary Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 476-481.	2.4	60
203	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in Anaplastic thyroid cancer. <i>Surgery</i> , 2012, 152, 1078-1087.	1.0	45
204	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1137-1147.	1.1	54
205	Anaplastic thyroid cancer therapy: dream or reality?. <i>Endocrine</i> , 2012, 42, 468-470.	1.1	10
206	2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2012, 1, 216-231.	1.2	88
207	Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2. <i>Journal of Oncology</i> , 2012, 2012, 1-15.	0.6	79
208	<i>RET/PTC</i> Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2012, 3, 54.	1.5	125
209	Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapeutic effect of vinorelbine in the medullary thyroid cancer TT cell line. <i>Molecular and Cellular Endocrinology</i> , 2012, 355, 41-48.	1.6	16
210	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5508-5508.	0.8	73
211	A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5591-5591.	0.8	24
212	New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 3-9.	1.8	48
213	<i>RET</i> point mutations in Thyroid Carcinoma. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
214	<i>RET</i> genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). <i>Clinical Endocrinology</i> , 2011, 74, 241-247.	1.2	101
215	Evidences that the polymorphism Pro282Ala within the tumor suppressor gene <i>WWOX</i> is a new risk factor for differentiated thyroid carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2816-2824.	2.3	28
216	Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters. <i>Thyroid</i> , 2011, 21, 1209-1215.	2.4	39

#	ARTICLE	IF	CITATIONS
217	CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2011, 164, 397-404.	1.9	28
218	In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, 603-612.	1.6	59
219	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5502-5502.	0.8	24
220	A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 5503-5503.	0.8	69
221	Carcinoma della tiroide. , 2011, , 403-420.		0
222	Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4197-4205.	1.8	162
223	Acute exogenous TSH administration stimulates leptin secretion in vivo. <i>European Journal of Endocrinology</i> , 2010, 163, 63-67.	1.9	56
224	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 963.	1.9	1
225	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 301-308.	1.9	111
226	Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1516-1527.	1.8	203
227	Correlazione genotipo-fenotipo nelle MEN 2: stato dell'arte dopo 15 anni di conoscenze. <i>L Endocrinologo</i> , 2010, 11, 94-101.	0.0	0
228	Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 579-586.	1.8	10
229	Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. <i>Journal of Pediatric Surgery</i> , 2010, 45, 1610-1616.	0.8	18
230	Ethics in Robotic Surgery and Telemedicine. , 2010, , 457-465.		1
231	Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. <i>Endocrine-Related Cancer</i> , 2009, 16, 1251-1260.	1.6	192
232	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3794-3801.	0.8	337
233	Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4171-4179.	1.8	78
234	A Morpho-Molecular Diagnosis of Papillary Thyroid Carcinoma: BRAF V600E Detection as an Important Tool in Preoperative Evaluation of Fine-Needle Aspirates. <i>Thyroid</i> , 2009, 19, 837-842.	2.4	81

#	ARTICLE	IF	CITATIONS
235	Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2- β -deoxycytidine and retinoic acid. <i>Molecular and Cellular Endocrinology</i> , 2009, 307, 142-148.	1.6	39
236	Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1618-1622.	1.8	93
237	Thyroid Cancer in Ukraine After the Chernobyl Accident: Incidence, Pathology, Treatment, and Molecular Biology. , 2009, , 305-316.		3
238	T cell responses to orbital antigens in thyroid-associated ophthalmopathy. <i>Clinical and Experimental Immunology</i> , 2008, 96, 329-334.	1.1	24
239	Routine serum calcitonin measurement in the evaluation of thyroid nodules. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 941-953.	2.2	78
240	Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. <i>Molecular and Cellular Endocrinology</i> , 2008, 291, 57-62.	1.6	54
241	Retinoic acid receptor β 2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2- β -deoxycytidine treatment. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 724-730.	1.8	19
242	Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 682-687.	1.8	478
243	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 511-520.	1.6	139
244	Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2729-2736.	1.8	50
245	BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3943-3949.	1.8	482
246	Anaplastic thyroid cancer: prevalence, diagnosis and treatment. <i>Minerva Endocrinologica</i> , 2008, 33, 341-57.	1.7	75
247	RET Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4725-4729.	1.8	236
248	Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 1099-1105.	1.6	48
249	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. <i>Human Pathology</i> , 2007, 38, 1482-1488.	1.1	18
250	Lymphocyte and Immature Dendritic Cell Infiltrates in Differentiated, Poorly Differentiated, and Undifferentiated Thyroid Carcinoma. <i>Thyroid</i> , 2007, 17, 389-393.	2.4	77
251	Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2007, 17, 381-388.	2.4	64
252	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2007, 54, 390.e1-390.e16.	0.8	0

#	ARTICLE	IF	CITATIONS
253	The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3511-3516.	1.8	93
254	Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4085-4090.	1.8	370
255	Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007, 21, 120-123.	1.3	54
256	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. <i>European Journal of Endocrinology</i> , 2006, 154, 787-803.	1.9	1,804
257	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 926-932.	1.8	405
258	Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 131-135.	1.8	27
259	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hurtle cell thyroid lesions: results from a series of 505 consecutive patients. <i>Clinical Endocrinology</i> , 2006, 66, 061109020454002-???	1.2	107
260	Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. <i>Endocrine-Related Cancer</i> , 2006, 13, 455-464.	1.6	207
261	Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2389-2395.	1.8	41
262	Medullary Thyroid Cancer: Diagnosis and Management. , 2006, , 255-279.		4
263	All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor β Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2403-2411.	1.8	41
264	Influence of Human Body Composition on Serum Peak Thyrotropin (TSH) after Recombinant Human TSH Administration in Patients with Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4047-4050.	1.8	26
265	RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin Concentration. <i>Thyroid</i> , 2005, 15, 1355-1361.	2.4	25
266	Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 124-127.	1.8	193
267	A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4810-4816.	1.8	18
268	Medullary and Papillary Tumors Are Frequently Associated in the Same Thyroid Gland without Evidence of Reciprocal Influence in Their Biologic Behavior. <i>Thyroid</i> , 2004, 14, 946-952.	2.4	60
269	RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3579-3584.	1.8	108
270	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. <i>Journal of Endocrinology</i> , 2004, 182, 479-484.	1.2	17

#	ARTICLE	IF	CITATIONS
271	Low Specificity of Blood Thyroglobulin Messenger Ribonucleic Acid Assay Prevents Its Use in the Follow-Up of Differentiated Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 33-39.	1.8	56
272	Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 163-168.	1.8	464
273	Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche. <i>L Endocrinologo</i> , 2004, 5, 39-46.	0.0	0
274	Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 866-869.	1.8	8
275	Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 557-561.	1.8	28
276	Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 636-642.	1.8	2
277	BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2414-2420.	1.8	259
278	Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5823-5827.	1.8	63
279	Authors'™ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules'™ Will the Law Answer before Endocrinologists Do?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4770-4770.	1.8	0
280	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. <i>Clinical Endocrinology</i> , 2003, 59, 500-506.	1.2	23
281	Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3668-3673.	1.8	386
282	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunocytochemistry in Cytologic and Pathologic Specimens. <i>Thyroid</i> , 2003, 13, 765-770.	2.4	51
283	Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. <i>European Journal of Endocrinology</i> , 2003, 148, 579-586.	1.9	16
284	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 748-754.	1.8	61
285	Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 892-899.	1.8	29
286	Biology and clinical application of the NIS gene. <i>Tumori</i> , 2003, 89, 523-8.	0.6	2
287	Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4160-4165.	1.8	90
288	Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1499-1501.	1.8	260

#	ARTICLE	IF	CITATIONS
289	Ablation of Thyroid Residues with 30 mCi ¹³¹ I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4063-4068.	1.8	170
290	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. <i>American Journal of Pathology</i> , 2002, 160, 247-254.	1.9	103
291	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness. <i>Surgery</i> , 2002, 132, 1070-1074.	1.0	199
292	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. <i>International Journal of Cancer</i> , 2002, 97, 608-614.	2.3	41
293	Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 445-447.	1.8	11
294	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2001, 145, 599-604.	1.9	50
295	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3211-3216.	1.8	234
296	Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic ¹³¹ I Whole Body Scan: Comparison of Patients Treated with High ¹³¹ I Activities Versus Untreated Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4092-4097.	1.8	222
297	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5686-5690.	1.8	167
298	Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients. <i>Thyroid</i> , 2001, 11, 877-881.	2.4	140
299	RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3211-3216.	1.8	186
300	New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2000, 53, 131-136.	1.2	17
301	N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. <i>Thyroid</i> , 2000, 10, 19-23.	2.4	159
302	Conditional Apoptosis Induced by Oncogenic Ras in Thyroid Cells. <i>Molecular Endocrinology</i> , 2000, 14, 1725-1738.	3.7	52
303	RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 328-338.	1.8	31
304	Involvement of Protein Kinase C μ (PKC μ) in Thyroid Cell Death. <i>Journal of Biological Chemistry</i> , 1999, 274, 23414-23425.	1.6	70
305	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998, 83, 2185-2193.	2.0	64
306	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998, 83, 2185-2193.	2.0	3

#	ARTICLE	IF	CITATIONS
307	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998, 83, 2185-93.	2.0	14
308	Identification of Rapid Turnover Transcripts Overexpressed in Thyroid Tumors and Thyroid Cancer Cell Lines: Use of a Targeted Differential RNA Display Method to Select for mRNA Subsets. <i>Nucleic Acids Research</i> , 1997, 25, 3823-3831.	6.5	38
309	Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). <i>Journal of Endocrinological Investigation</i> , 1996, 19, 230-235.	1.8	4
310	Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 1619-1622.	1.8	140
311	Post-surgical follow-up of differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 165-166.	1.8	12
312	Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. <i>Surgery</i> , 1995, 118, 1031-1035.	1.0	80
313	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 867-871.	1.8	56
314	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. <i>European Journal of Cancer</i> , 1994, 30, 171-174.	1.3	37
315	Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 826-829.	1.8	227
316	Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 867-871.	1.8	48
317	Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 499-503.	1.8	84
318	Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 329-332.	1.8	35
319	Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 511-519.	1.8	47
320	Muscle autoantigens in thyroid associated ophthalmopathy: The limits of molecular genetics. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 533-540.	1.8	16
321	Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 1401-1404.	1.8	199
322	Expression of calcitonin gene-related peptide in medullary thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 539-542.	1.8	10
323	Medullary Thyroid Cancer: <i>An Immunohistochemical and Humoral Study Using Six Separate Antigens</i>. <i>American Journal of Clinical Pathology</i> , 1991, 95, 300-308.	0.4	82
324	Demonstration of the Existence of the Alternatively Spliced Form of Thyroid Peroxidase in Normal Thyroid*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 700-702.	1.8	26

#	ARTICLE	IF	CITATIONS
325	Studies with Recombinant Autoepitopes of Thyroid Peroxidase: Evidence Suggesting an Epitope Shared Between the Thyroid and the Gastric Parietal Cell. <i>Autoimmunity</i> , 1990, 8, 65-70.	1.2	37
326	Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. <i>Cancer</i> , 1989, 63, 1189-1195.	2.0	46
327	Thyroid carcinoma in thyrotoxic patients treated by surgery. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 107-112.	1.8	116
328	Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumour outcome. <i>European Journal of Endocrinology</i> , 1988, 119, 373-380.	1.9	140
329	Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. <i>Journal of Nuclear Medicine</i> , 1987, 28, 1888-91.	2.8	168